Abstract
DNA-binding compounds are of extraordinary importance in medicine, accounting for a substantial portion of antitumor drugs in clinical usage. However, their mechanisms of action remain sometimes incompletely understood. This review critically examines two broad classes of molecules that bind noncovalently to DNA: intercalators and groove binders. Intercalators bind to DNA by inserting their chromophore moiety between two consecutive base pairs, whereas groove binders fit into the grooves of DNA. Noncovalent DNAinteractive drugs can recognize certain supramolecular DNA structures such as the Gquadruplexes found in telomeres and in numerous gene promoters, and they can act as topoisomerase I and II poisons. We discuss how DNA-binding compounds affect transcription and compete with protein factors for binding to consensus binding sites in gene promoters both in vitro and in cultured cancer cells. Moreover, we comment on the design of molecules that can tightly and specifically bind to any desired target DNA, such as various hairpin polyamides which efficacy as chemotherapeutic agents is being evaluated. At present, genome-wide studies, which provide details of events that may influence both cancer progression and therapeutic outcome, are a common way used to analyze the effects of DNA-binding compounds. A conclusive feature that emerges from reviewing the information on DNA-binding compounds is that both natural sources and chemical approaches can be productively used to obtain drugs to manipulate gene expression in cancer cells.
Keywords: Antitumor chemotherapy, DNA-binding drugs, DNA recognition, Drug discovery, Mechanism of action, Sequence specificity.
Current Medicinal Chemistry
Title:Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Volume: 23 Issue: 36
Author(s): José Portugal and Francisca Barceló
Affiliation:
Keywords: Antitumor chemotherapy, DNA-binding drugs, DNA recognition, Drug discovery, Mechanism of action, Sequence specificity.
Abstract: DNA-binding compounds are of extraordinary importance in medicine, accounting for a substantial portion of antitumor drugs in clinical usage. However, their mechanisms of action remain sometimes incompletely understood. This review critically examines two broad classes of molecules that bind noncovalently to DNA: intercalators and groove binders. Intercalators bind to DNA by inserting their chromophore moiety between two consecutive base pairs, whereas groove binders fit into the grooves of DNA. Noncovalent DNAinteractive drugs can recognize certain supramolecular DNA structures such as the Gquadruplexes found in telomeres and in numerous gene promoters, and they can act as topoisomerase I and II poisons. We discuss how DNA-binding compounds affect transcription and compete with protein factors for binding to consensus binding sites in gene promoters both in vitro and in cultured cancer cells. Moreover, we comment on the design of molecules that can tightly and specifically bind to any desired target DNA, such as various hairpin polyamides which efficacy as chemotherapeutic agents is being evaluated. At present, genome-wide studies, which provide details of events that may influence both cancer progression and therapeutic outcome, are a common way used to analyze the effects of DNA-binding compounds. A conclusive feature that emerges from reviewing the information on DNA-binding compounds is that both natural sources and chemical approaches can be productively used to obtain drugs to manipulate gene expression in cancer cells.
Export Options
About this article
Cite this article as:
Portugal José and Barceló Francisca, Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents, Current Medicinal Chemistry 2016; 23 (36) . https://dx.doi.org/10.2174/0929867323666160902153511
DOI https://dx.doi.org/10.2174/0929867323666160902153511 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents in Cancer Stem Cells
Recent Patents on Biomarkers CD38 in Chronic Lymphocytic Leukemia: From Bench to Bedside?
Mini-Reviews in Medicinal Chemistry Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Infectious Disorders - Drug Targets Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Analytical Methods of Bioactive Metabolites Produced by Plants and Microorganisms
Current Pharmaceutical Analysis The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State
Vascular Disease Prevention (Discontinued) Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics